The primary purpose of this role is to contribute to the definition, execution, and delivery of the Global Market Access and Pricing (GMAP) strategy for amlitelimab in Atopic Dermatitis, with a clear focus on end-to-end launch readiness aligned to the Sanofi Integrated Launch Cycle (SILC).
$178,500.00 - $257,833.33; Not specified; Not specified
Must-have
Nice-to-have
Not specified